Prosecution Insights
Last updated: October 01, 2026
Application No. 18/553,817

ENZYME COMPOSITION

Non-Final OA §DP
Filed
Oct 03, 2023
Priority
Apr 06, 2021 — EU 21166963.5 +1 more
Examiner
FRONDA, CHRISTIAN L
Art Unit
1652
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
DSM IP Assets B.V.
OA Round
2 (Non-Final)
82%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
97%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allowance Rate
1122 granted / 1361 resolved
+22.4% vs TC avg
Moderate +14% lift
Without
With
+14.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
44 currently pending
Career history
1398
Total Applications
across all art units

Statute-Specific Performance

§101
5.2%
-34.8% vs TC avg
§103
25.7%
-14.3% vs TC avg
§102
7.7%
-32.3% vs TC avg
§112
38.3%
-1.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1361 resolved cases

Office Action

§DP
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 10, 12-30 are pending and under consideration in this Office Action. The previous objection to the title has been withdrawn in view of the amendment to the title filed 04/15/2026. In view of the claim amendments and arguments filed 04/15/2026 all previous claim objections and/or claim rejections have been withdrawn in favor of the instant rejection of the claims stated below. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). Claims 10, 12-30 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 9, 10, 12-15, 21 of Application Serial No. 18553810, claims 9-15 of Application Serial No. 18553801. Applicant’s statement filed 04/15/2026 that applicant is willing to consider filing a terminal disclaimer. However, until a terminal disclaimer is filed the claims are rejected as stated below. Although the conflicting claims are not identical, they are not patentably distinct from each other for the following reasons. The claims are broad and widely varying and encompass any process for producing any fermentation product from any cellulosic material, which process comprises a) hydrolysing the cellulosic material with any enzyme composition to obtain any sugar, b) fermenting the obtained sugar by contacting the obtained sugar with any fermenting microorganism to produce the fermentation product, and c) optionally, recovering the fermentation product, wherein the enzyme composition comprises any glucoamylase comprising the amino acid sequence of any mature polypeptide of SEQ ID NO: 2, any cellobiohydrolase I comprising the amino acid sequence of any mature polypeptide of SEQ ID NO: 4, and any beta-glucosidase. The claims and/or specification of the copending applications teach the claimed process for producing a fermentation product from a cellulosic material, which process comprises a) hydrolysing the cellulosic material with an enzyme composition to obtain a sugar, b) fermenting the obtained sugar by contacting the obtained sugar with a fermenting microorganism to produce the fermentation product, and c) optionally, recovering the fermentation product. Thus, the teachings anticipate the claimed invention. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion No claim is allowed. THIS ACTION IS MADE FINAL Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L Fronda whose telephone number is (571)272 0929. The examiner can normally be reached Monday-Thursday and alternate Fridays between 9:00AM-5:00PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Mondesi can be reached on (408)918-7584. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHRISTIAN L FRONDA/Primary Examiner, Art Unit 1652
Read full office action

Prosecution Timeline

Oct 03, 2023
Application Filed
Feb 12, 2026
Non-Final Rejection mailed — §DP
Apr 15, 2026
Response Filed
Jul 15, 2026
Final Rejection mailed — §DP
Aug 10, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12742189
RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF TETRAKETIDE DERIVATIVES
5y 2m to grant Granted Sep 22, 2026
Patent 12742150
METHOD FOR PRESERVING FERMENTATION BROTH OF ENGINEERED STRAIN OF D-PSICOSE-3-EPIMERASE
3y 0m to grant Granted Sep 22, 2026
Patent 12735682
Modified glutamate dehydrogenase and the use thereof
3y 8m to grant Granted Sep 15, 2026
Patent 12709743
Novel CRISPR-Cas delta enzyme and system
1y 8m to grant Granted Aug 18, 2026
Patent 12703860
Terminal Deoxynucleotidyl Transferase Variants and Uses Thereof
3y 9m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
82%
Grant Probability
97%
With Interview (+14.2%)
2y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1361 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month